Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that it has entered into a settlement agreement with Actavis Laboratories FL (“Actavis”) resolving patent litigation related …
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that, due to the impending loss of exclusivity of TREXIMET® (sumatriptan and naproxen sodium), the Company is …
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) announced that Dr.
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced financial results for the three and six months ended June 30, 2017. Second Quarter 2017 Financial Highlights: Second …
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced today that it has been added to the Russell Microcap® index following the annual reconstitution, which took …
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) shares are tumbling 25% in after-hours trading after the drug maker said that a failure to raise capital and repay all …
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that, due to a manufacturing issue with its supplier, the Company expects that the 20mg strength of …
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) announced financial results for the three and twelve months ended December 31, 2016.
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) investors have a smile on their faces Thursday morning, after the pharmaceutical firm announced that it received a favorable …
Cerulean Pharma Inc (NASDAQ:CERU) are catapulting 60% after the cancer drug-maker has decided to confront recent missteps with the consideration of M&A possibilities. …
